Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost Sodium Modified Release; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Torrance, California • Naperville, Illinois • New York, New York + 3 more

Conditions: Advanced Colorectal Cancer Expressing HER2
Interventions: Trastuzumab Rezetecan (SHR-A1811) injection; high dose, Trastuzumab Rezetecan (SHR-A1811) injection; low dose; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epilepsy
Interventions: cannabidiol, Blood Test; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 2 Years to 16 Years
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: Neuroblastoma, Cancer
Interventions: Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib; Procedure · Genetic · Other + 2 more
Lead sponsor: Yael P Mosse; Other
Eligibility: 1 Year to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions: Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®; Diagnostic Test · Drug
Lead sponsor: Roderick Tan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
Interventions: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Acute Mountain Sickness and Fatigue
Interventions: Aminophylline 400 mg, Ambrisentan 5 mg, Placebo; Drug · Other
Lead sponsor: Robert J Noveck, M.D.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more

Conditions: Lymphoma
Interventions: Rituxan, BEAM, Autologous stem cell transplant; Drug · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
Interventions: ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions: Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 7 Years to 12 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Cincinnati, Ohio • Houston, Texas

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: High Dose Device, Low Dose Device, Placebo Device; Drug · Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone; Genetic · Drug
Lead sponsor: Vector Y Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 3 more

Conditions: Dystocia
Interventions: Oxytocin, Sodium Chloride 0.9%; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cervical Dystonia
Interventions: DaxibotulinumtoxinA for injection, Placebo; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more

Conditions: COVID-19, Long Haul
Interventions: Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach; Drug · Diagnostic Test · Biological + 3 more
Lead sponsor: Well- Konnect Healthcare Services and Research Firm; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 72
States / cities: Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more

Conditions: Myeloma
Interventions: G-CSF, Plerixafor, Apheresis, Melphalan, Stem cell re-infusion, Basiliximab, CliniMACS CD25 microbeads and cell sorter; Drug · Procedure · Device
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gaucher Disease, Type 2
Interventions: LY3884961, Methylprednisolone, Sirolimus, Prednisone; Genetic · Drug
Lead sponsor: Prevail Therapeutics; Industry
Eligibility: 0 Months to 24 Months
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Oakland, California • Minneapolis, Minnesota • New York, New York + 2 more

Conditions: Prostate Cancer
Interventions: pembrolizumab, Low dose prostate radiation, Radical Prostatectomy; Drug · Radiation · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Demoralization
Interventions: Psilocybin, Ketamine; Drug
Lead sponsor: Charles S. Grob, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Greenbrae, California • Los Angeles, California • San Francisco, California + 2 more

Conditions: Ototoxicity, Drug-Induced
Interventions: ORC-13661, Placebo; Drug
Lead sponsor: Kevin Winthrop; Other
Eligibility: 18 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more

Conditions: Skin Infection, Bacterial Infection
Interventions: Daptomycin, Brilacidin; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 1 more

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2

Treatment of Drug Resistant Epilepsy

Next Generation Personalized Neuroblastoma Therapy

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Interventions for Children With Attention and Reading Disorders

Safety and Efficacy of a Glaucoma Drug Delivery System

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

Stem Cell Transplantation for Patients With Multiple Myeloma

Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)

Pragmatic Trial of Psilocybin Therapy in Palliative Care

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma